These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26696548)

  • 1. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1.
    Beekman AM; Howell LA
    ChemMedChem; 2016 Apr; 11(8):802-13. PubMed ID: 26696548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.
    Cohen NA; Stewart ML; Gavathiotis E; Tepper JL; Bruekner SR; Koss B; Opferman JT; Walensky LD
    Chem Biol; 2012 Sep; 19(9):1175-86. PubMed ID: 22999885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
    Beekman AM; O'Connell MA; Howell LA
    ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
    Li K
    Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexibility enables to discriminate between ligands: Lessons from structural ensembles of Bcl-xl and Mcl-1.
    Maity A; Majumdar S; Ghosh Dastidar S
    Comput Biol Chem; 2018 Dec; 77():17-27. PubMed ID: 30195235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
    Modi V; Sankararamakrishnan R
    J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains.
    Rezaei Araghi R; Ryan JA; Letai A; Keating AE
    ACS Chem Biol; 2016 May; 11(5):1238-44. PubMed ID: 26854535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells.
    Foight GW; Ryan JA; Gullá SV; Letai A; Keating AE
    ACS Chem Biol; 2014 Sep; 9(9):1962-8. PubMed ID: 25052212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
    Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.
    Rezaei Araghi R; Bird GH; Ryan JA; Jenson JM; Godes M; Pritz JR; Grant RA; Letai A; Walensky LD; Keating AE
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E886-E895. PubMed ID: 29339518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.
    Pelz NF; Bian Z; Zhao B; Shaw S; Tarr JC; Belmar J; Gregg C; Camper DV; Goodwin CM; Arnold AL; Sensintaffar JL; Friberg A; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2016 Mar; 59(5):2054-66. PubMed ID: 26878343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.
    Drennen B; Scheenstra JA; Yap JL; Chen L; Lanning ME; Roth BM; Wilder PT; Fletcher S
    ChemMedChem; 2016 Apr; 11(8):827-33. PubMed ID: 26844930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
    Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
    Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-X
    Reddy CN; Manzar N; Ateeq B; Sankararamakrishnan R
    Biochemistry; 2020 Nov; 59(45):4379-4394. PubMed ID: 33146015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.